Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMOX1 | P09601 | 1/20 | 0.36 |
| ▸ | ACACB | O00763 | 3/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.30 |
| ▸ | RBP4 | P02753 | 1/20 | 0.30 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.30 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5962243 | 0.84 | CYP2C19 (0.34) | HMOX1ACACBEPHX2 | |
| SCHEMBL4107214 | 0.80 | EPHX2 (0.37) | HMOX1EPHX2RBP4HCRTR1 | |
| SCHEMBL4593696 | 0.79 | GPR119 (0.34) | ACACBEPHX2HCRTR1 | |
| SCHEMBL8530303 | 0.79 | LPL (0.47) | ACACB | |
| SCHEMBL15789122 | 0.78 | — | — | |
| SCHEMBL28053867 | 0.78 | OPRK1 (0.41) | EPHX2CHRM2CHRM3 | |
| SCHEMBL8511076 | 0.76 | DGAT1 (0.45) | HMOX1HCRTR1 | |
| SCHEMBL8536867 | 0.76 | CCR5 (0.40) | EPHX2CHRM2CHRM3 | |
| SCHEMBL4593318 | 0.75 | LOXL2 (0.30) | — | |
| SCHEMBL2196095 | 0.75 | OPRK1 (0.39) | ACACBLNPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1717230-B1 | FUSED-RING 4-OXOPYRIMIDINE DERIVATIVE | MSD KK (JP) | 2014-08-06 | — | — | EP | disclosed |
| US-8268842-B2 | Fused ring 4-oxopyrimidine derivative | MSD K.K. (JP) | 2012-09-18 | — | — | US | disclosed |
| US-20090209562-A1 | Fused ring 4-oxopyrimidine derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-08-20 | — | — | US | disclosed |
| US-7521455-B2 | Fused ring 4-oxopyrimidine derivative | BANYU PHARMACEUTICAL CO. LTD. (JP) | 2009-04-21 | — | — | US | disclosed |
| EP-1717230-A1 | FUSED-RING 4-OXOPYRIMIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-11-02 | — | — | EP | disclosed |
| US-20050182045-A1 | Fused ring 4-oxopyrimidine derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050182045-A1 | Fused ring 4-oxopyrimidine derivative | HRH4, HRH2, HRH3 | HMOX1 1118/4885ACACB 4319/4885EPHX2 812/4885 |
| US-20090209562-A1 | Fused ring 4-oxopyrimidine derivative | HRH4, HRH2, HRH3 | HMOX1 1118/4885ACACB 4319/4885EPHX2 812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.